Navigation Links
Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
Date:5/7/2012

NEW YORK, May 7, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease, today announced that a conference call will be held on Wednesday, May 9, 2012 at 8:30 a.m. EDT to discuss results for the first quarter ended March 31, 2012 and a business outlook for the remainder of 2012. Ron Bentsur, Chief Executive Officer of Keryx, will host the call.

In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

Keryx will announce its financial results for this period in a press release to be issued prior to the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

 


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel of ... reacts to a recent study, which shows how grief in ... http://photos.prnewswire.com/prnh/20140723/129709 According to US ... are more likely than others to grow up overweight or ... There were two specific types of stress that caused ...
(Date:7/24/2014)...  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... conference call to report its second quarter 2014 financial ... and outlook on Thursday, August 7, 2014 at 8:30 ... The call can be accessed by dialing ... prior to the start of the call and providing ...
(Date:7/24/2014)... , Germany , and ... -- , Exclusive global license ... for SF3B1 mutations, including next-generation sequencing (NGS) gene panels, ... to be targeted by new test, indicate favorable prognosis ... syndromes  QIAGEN sees potential for developing companion ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5
... Dec. 5, 2010 Pfizer Inc. (NYSE: ... has elected Ian C. Read, 57, currently head of ... Officer and Director. Mr. Read succeeds Jeffrey B. Kindler, ... (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) The Board,s Lead Independent Director, ...
... The Infectious Disease Research Institute (IDRI) has ... Advance Research and Development Authority (BARDA). IDRI,s work will ... to $8.5 million over three years when further development ... agency. "BARDA is supporting an important ...
Cached Medicine Technology:Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 2Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 3Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 4IDRI Awarded Contract from BARDA to Develop Next Generation Adjuvants for Pandemic Influenza 2
(Date:7/25/2014)... are more easily distracted during thinking and memory tasks ... any type of memory test administered reveals a decline ... co-author Randi Martin, professor of psychology at Rice University, ... said, this study shows that "environmental interference" has a ... younger adults. The study included 60 seniors, aged ...
(Date:7/25/2014)... USA (PRWEB) July 25, 2014 As reported ... Use, OD Deaths Increase (7/20), Michigan has seen a nearly ... four years. While the count was 271 between 1999 and ... range. DEA Agents believe that, like other states, drug users ... the drug via prescription pills. He compared the price of ...
(Date:7/25/2014)... Florida Hospital and MOSI officially announced a transformational partnership ... come and make a difference in the Tampa Bay community. ... to provide the support needed to keep the science center ... the IMAX Dome Theatre from film to a state-of-the-art digital ... Theatre in the state of Florida, and it is one ...
(Date:7/25/2014)... 2014 Merrill Corporation ( http://www.merrillcorp.com ... for the financial, legal, healthcare and other corporate ... business, Merrill DataSite, has been recognized as the ... at the M&A Awards 2014 event. ... entrepreneurs, management teams, advisors and financiers as they ...
(Date:7/25/2014)... 2014 A new study conducted by the ... 39 percent of all children in the survey under the age ... looked at 2,505 children during the years of 2011 and 2013. ... age. The final result was that about two out of ... these children were from lower-income families and were of East Asian ...
Breaking Medicine News(10 mins):Health News:Distractions Seem More Troublesome With Age 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3
... collaborators have shown how to predict if a child ... being treated for cancer or another catastrophic disease is ... will help clinicians improve guidelines for managing these infected ... pneumonia among infants, children and adults during winter, frequently ...
... Naviscan PET Systems, a privately,held company and the ... Paul J. Mirabella as Chairman of the Board, in,addition ... the,addition of Dr. Abhi Acharya to the Board of ... Chief Executive Officer,in July 2007 bringing 32 years of ...
... 4 The sponsors of two of,Pittsburgh,s finest long ... General,s Office of approval of their intention to,bring their ... 1, 2008, the Sisters of the Holy Spirit and ... a 186 bed not,for profit long term care facility ...
... has identified a previously unsuspected protein as a key ... cancer therapy. The study, published by Cell Press in ... understanding of the molecular response to breast cancer therapies ... estrogen receptor and are dependent on estrogen signaling. Drugs ...
... YORK, February 4, 2008 The Juvenile Diabetes ... of type 1 diabetes research, announced today that ... company based in Winston-Salem, N.C. that focuses on ... Through its Industry Discovery and Development Partnership Program, ...
... to later learning deficits , , MONDAY, Feb. 4 (HealthDay ... exposed to alcohol during pregnancy but who don,t have ... a new study suggests. , "Eyeblink conditioning (EBC) ... a conditioned stimulus, such as a tone, with an ...
Cached Medicine News:Health News:St. Jude finds risk factors for severe RSV infection in immunocompromised children 2Health News:St. Jude finds risk factors for severe RSV infection in immunocompromised children 3Health News:Naviscan Announces a New Chairman and Board Member 2Health News:Pennsylvania Attorney General Approves Vincentian Collaborative System-Marian Manor Integration 2Health News:Unsuspected protein determines resistance to breast cancer treatment 2Health News:JDRF partners with Plureon to explore generating insulin-producing cells from adult stem cells 2Health News:Eye Blinks May ID Fetal Alcohol Exposure 2
... an automatic petri dish streaking machine. ... up to 180 pre inoculated petri ... in substantial cost savings. The ISOPLATER® ... standardizes streaking procedures and increases safety ...
Data review and analysis is carried out with the Acquidata Uromac software already supplied with Acquidata Uromac Lab based urodynamics systems...
A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
... for any clinical setting, offering an ... UDS procedure. Customize Delphis™ to your ... a Pocket PC, a Touchpad PC ... wireless technology allows you to focus ...
Medicine Products: